Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
S. N. JOGDAND 
1/10/2014 
BIOTECH SUPPORT SERVICES (BSS), INDIA presents - 
BIO-ENTREPRENEURS OF INDIA
2 
Roughly speaking Bio-Entrepreneurs in India are: 
 Pre-Modern Biotech Entrepreneurs (Before 1980s) 
 The First Wave o...
3 
List of Bio-Entrepreuners Presented 
1 
Mr. Ramanbhai Patel, Zydus Cadilla 
2 
Piyush Palkhiwala, Maps Enzymes 
3 
Mr. ...
4 
Mr. Ramanbhai Patel 
Founder Chairman, Zydus Cadila 
Zydus Cadila develops and manufactures a large range of pharmaceut...
5 
Piyush Palkhiwala, 
Chairman & Managing Director, 
Maps Enzymes, Gujarat 
In 1975, Mr. Piyush Palkhiwala started Maps I...
6 
Mr. L. C. Rathi, 
Founder, 
Advanced Enzyme Technologies Ltd. (AETL) 
(Managing Director) 
Mr. L. C. Rathi, is the fore...
7 
Dr. Bala S. Manian 
Chairman and Founder, Reametrix Inc. 
Serial Entrepreneur 
Dr Manian holds more than 30 patents, ma...
8 
Dr. Cyrus S. Poonawala, 
Chairman, Serum Institute of India, Pune 
World's largest makers of pediatric vaccines 
Dr. Po...
9 
Dr. Pradip K. Desai 
Founder Chairman, Span Diagnostics, Surat, Gujarat 
He is MD (Pathology) from B. J. Medical Colleg...
10 
Kiran Muzumdar-Shaw 
CEO – Biocon India - Chairman & Managing Director 
Value: Rs 4,843 crore. The country's largest b...
11 
Mr. Arunachalam Muthu, 
Managing Director 
Saf Yeast Co Pvt. Ltd. (SYCPL) 
Muthu is also credited with personally tran...
12 
K. I. Varaprasad REDDY, Founder, Shantha Biotechnics, Hyderabad 
Value: Rs 725 crore* By producing India's first genet...
13 
Dr. Krishna M. Ella, 
Bharat Biotech International Ltd., Hyderabad 
Scientist-turned-serial entrepreneur 
Krishna M El...
14 
Ms. Anuradha Acharya, 
Founder & CEO (2000-2013) 
Ocimum Biosolutions 
Currently CEO at Mapmygenome.in, YGL- WEF, Hyde...
15 
Villoo Morwalla Patel CEO, MD, Avesthagen Gengraine 
Value: Rs 600 crore* A scientist-turned- entrepreneur, Patel has ...
16 
Dr Mugasimangalam C Raja President, Founder and CEO, 
Genotypic Technology 
Dr Mugasimangalam C Raja, holds a Masters ...
17 
Swati Piramal, Vice Chairperson, Nicholas Piramal 
Value: Rs 120 crore* The Mumbai-based firm is involved in a range o...
18 
Rajesh Jain, Jt. Managing Director, Panacea Biotec Ltd, New Delhi 
Company was started in 1984. Value: Rs 260 crore. E...
19 
Dr BVLS Prasad 
Helix Genomics Pvt. Ltd. (HGPL) Hyderabad, India 
Helix Genomics Pvt. Ltd. (HGPL), India is a universi...
20 
Dr. Shama Bhat 
Founder, Chairman and Managing Director, Bhat Laboratories 
The urge of doing something different than...
21 
Ramakrishna V. Modali – Founder, President 
Bioserve Biotechnologies (I) Pvt. Ltd., Hyderabad 
Since BioServe's incept...
22 
Dr. Muhammed Majeed 
Founder and Managing Director, 
Sami Labs Limited 
Established in 1991. Now it has 500 people wor...
23 
VIJAY CHANDRU, Ph.D 
Co-founder, Chairman and CEO 
Strand Life Sciences (Strand Genomics) 
Company was founded in the ...
24 
K. V. Subrahmanyam 
President & CEO, Reliance Life Sciences 
K.V. Subramaniam is a Chemical Engineer from Madras Unive...
25 
K. K. Narayanan 
Managing Director, 
Metahelix Life Sciences, Bangalore 
Mr. K. K. Narayanan started Metahelix along w...
26 
A V Rama Rao 
Founder, Chairman & Managing Director, Avra Laboratories Private Limited 
Rama Rao is an eminent Indian ...
27 
Sandeep Saxena, CEO and founder 
Acton Biotech (India) Pvt Ltd. Pune 
Business - Diagnostics 
Always aspired to be an ...
28 
Dr. Rama Mukerjee 
Ara healthcare Pvt. Ltd. Gurgaon 
Started in 2007 
Number of Employees – 48 
Dr. Rama Mukherjee, Ph...
29 
Supreet Deshpande 
CEO, Vlife Sciences Technologies Pvt. Ltd, Novalead Pharma, Pune 
Started in 2007, Business: Drug D...
30 
Dr. Shesheer Kumar 
RAS Lifesciences, Hyderabad 
MD & CEO 
Business – Molecular Diagnostics 
Started in 2008, Number o...
31 
P Gopal Krishnan, MD 
KARD Scientific India, Pune 
KARD Scientific offers its superior contract research service at re...
32 
Naveen Kulkarni, Founder, CEO 
Polyclone BioServices, Bangalore 
Naveen Kulkarni has a Masters in Applied Science (Lif...
33 
Dr. Raghavendra Gaikaiwari 
Chairman and Managing Director, 
Hi Tech Biosciences India Ltd. 
Mr. R.P. Gaikaiwari, an M...
34 
Chandrashekhar Kulkarni 
MITCON Biotechnology Business Incubation Center, Pune 
The center was set up in 2004 with the...
35 
Dr Raj Singh, 
President and Chief Executive Officer, Vivo Biosciences India 
Vivo Biosciences India is a subsidiary o...
36 
Shrikumar Suryanarayan 
chairman, Sea6 Energy 
At 23, he joined Biocon and directed its R&D ethos and enzymes conquest...
37 
Dr. N. Barathi 
Scientist and Entrepreneur 
Energy Plantation consultant 
GROWMORE BIOTECH Ltd., Hosur, Tamil Nadu 
Dr...
38 
B. V. Ravi Kumar 
XCyton Diagnostics 
Dr. B.V. Ravi Kumar - is the founder of XCyton, and functions in the capacity of...
39 
Ravi Kshirsagar 
Founder and Principal Consultant Inbiosys Consulting 
He is qualified from Project Management Institu...
40 
Dr P. M. Murali Managing Director and CEO, 
Evolva Biotech 
He received a PhD in Microbiology and Microbial Technology...
41 
Dr. Rajeev Soni 
President, COO, Premas Biotech 
Rajeev Soni is a Ph.D. in Molecular Biology and Biotechnology from th...
42 
Taher Abbasi (Co-Founder and CEO) 
Pradeep Fernandes (Co-Founder & President) 
Cellworks Group Inc. 
Cellworks was fou...
43 
Sachin Purohit 
Founder, Managing Director, 
Geneombio Technologies, Pune, India 
Resilient Cosmeceuticals Pvt. Ltd. 
...
44 
Jitendra N Verma 
Founder & Managing Director, 
Lifecare Innovations (P) Ltd. 
He is M.Sc. from Allahabad University a...
45 
Mr. Vinod Wahi 
Founder Chairman & CEO, 
KHC Healthcare India Private Limited 
The company was established in 2005. 
H...
46 
Dr Mallik Sundaram, 
President and CEO (Founder), 
Mitra Biotech 
Company started in 2008 and has made commendable pro...
47 
Founders, Prof Shiladitya Sengupta and Dr. Raghunath Mashelkar 
Invictus Oncology, New Delhi 
Prof Shiladitya Sengupta...
48 
Dr Binay Panda and Dr Vijay Chandru (CEO of Strand Life Sciences) 
Genomics Application and Informatics Technology Lab...
49 
Mr. R.P Krishnamachari 
Founder, Managing Director / CEO 
Tex Biosciences (P) Limited 
Mr. Krishnamachari is the found...
50 
Dr Mosuvan Kuppusamy 
Founder, CSO, Managing Director, Tergene Biotech 
Dr Mosuvan Kuppusamy, is a well-known biotechn...
Bioentrepreneurs of india
Bioentrepreneurs of india
Bioentrepreneurs of india
Upcoming SlideShare
Loading in …5
×

Bioentrepreneurs of india

4,565 views

Published on

Brief Profiles of 50 Bio-entrepreneurs of India along with their company information. Biotechnology in India is in nascent stage. India has around 800 biotech companies out of which only 50 are presented here. They represent all the waves of biotech growth in India.

Bioentrepreneurs of india

  1. 1. S. N. JOGDAND 1/10/2014 BIOTECH SUPPORT SERVICES (BSS), INDIA presents - BIO-ENTREPRENEURS OF INDIA
  2. 2. 2 Roughly speaking Bio-Entrepreneurs in India are:  Pre-Modern Biotech Entrepreneurs (Before 1980s)  The First Wave of biotech Entrepreneurs - the late 1990s  The Second Wave of biotech Entrepreneurs From 2004-06. Attributes expected in Modern Entrepreneurs: Passion, Curiosity, Sponges, Optimism, ―I can Do It‖ Attitude, Forward-looking, Careful about money, Start at young age, Competitive, Time-conscious, Risk-takers, Usually Loners, Professional, High Energy, Flexible, Nurture entrepreneurial spirit, Confident Goal-setters, Persistent, Learn from failures, Self Responsibility, Resource Utilization, Multi-skilled, Multidimensional, Open to embracing changes “Ideal" entrepreneurial personality: Successful entrepreneurs can be  analytical or intuitive,  risk-averse or thrill seeking,  gregarious and taciturn Entrepreneurial instinct expresses - in spite of any Background What is interesting in wave of biotechs is that founders may come from altogether different background to realize their entrepreneurial dreams. Some leave their posh positions for starting new ventures.  Dr. Cyrus Poonawala (Serum Institute) Commerce background, Interests in Race Horses‘ Breeding  Gopal Krishnan (Kard Scientific India) Chartered Accountant  Biovel Group with Marketing Background  Vinod Wahi (KanHealthcare) Ex- chief of Wipro BioMed  Dr. Anil Paul Kariath (Biozeen) Former Managing Director of Sartorious India  DA Prasanna (Manipal Acunova) Wipro Funding constraints can be overcome - Indian VCs Support matured or well-run Companies and not early stage companies. The entrepreneurial spirit seems to mushroom unabated, despite funding constraints. They face problem as start-up, and thereafter for expansion. Many of them faced it including Kiran Muzumdar-Shaw. Now there is Government funding available for even start-ups Entrepreneur need not be the founder of a company but he is efficient user of resources and can create value in the organization.
  3. 3. 3 List of Bio-Entrepreuners Presented 1 Mr. Ramanbhai Patel, Zydus Cadilla 2 Piyush Palkhiwala, Maps Enzymes 3 Mr. L. C. Rathi, Advanced Enzymes 4 Dr. Bala S. Manian, Reametrix Inc. 5 Dr. Cyrus Poonawala, Serum Insti. 6 Dr.Pradip Desai, Span Diagnostics 7 Kiran Muzumdar-Shaw, Biocon Ltd. 8 Mr. Arunachalam Muthu, SAF Yeast 9 K. Varaprasad Reddy, Shantha Biot. 10 Dr. Krishna Ella, Bharat Biotech 11 Ms. Anuradha Acharya, Ocimum 12 Villoo Morwala Patel, Avesthagen 13 Dr. M.C. Raja Genotypic Technology 14 Swati Piramal, Nicholas Piramal 15 Rajesh Jain, Panacea Biotec 16 Dr. BVLS Prasad, Helix Genomics 17 Dr. Shama Bhat, Bhat Laboratories 18 Ramkrishna Modali, Bioserve 19 Dr. Muhammed Majid, Sami Labs 20 Vijay Chandru, Strand Life Sciences 21 K. V. Subrahmanyam, Reliance Life - 22 K. K. Narayanan, Metahelix Life Sci. 23 AV. Rama Rao, Avra Laboratories 24 Sandeep Saxena, Acton Biotech 25 Dr. Rama Mukerjee, Ara Healthcare 26 Supreet Deshpande, VLife Sciences 27 Dr. Shesheer Kumar, RAS Lifesci. 28 P. Gopal Krishnan, Kard Scientific 29 Naveen Kulkarni, Polyclone Services 30 Dr. Raghavendra Gaikaiwari Hi Tech 31 Chandrashekhar Kulkarni, MITCON 32 Dr. Raj Singh, Vivo Biosciences 33 Shrikumar Suryanarayan, Sea6 Energy 34 Dr. N. Barathi, Growmore Biotech 35 B. V. Ravikumar, XCyton Diagnostics 36 Ravi Kshirsagar, Inbiosys Consulting 37 Dr. P. M. Murali, Evolva Biotech 38 Dr. Rajiv Soni, Premas Biotech 39 Taher Abbasi, Cellworks Group Inc. 40 Sachin Purohit, Geneombio Techn. 41 Jitendra Verma, Lifecare Innovations 42 Vinod Wahi, KHC Healthcare 43 Dr. Mallik Sunderm, Mitra Biotech 44 Dr. Shiladitya Sengupta, Invictus Onco. 45 Dr. Binit Panda, GANIT Labs 46 Mr. R. P. Krishnamachari, Tex Biosci. 47 Dr. Mosuvan Kuppusamy, Tergene 48 Mr. R. Narayanan, XCode Life Sci. 49 KVSS SAIRAM – RAM, Vaishnavi 50 Anand Daga, Aumgene Biosciences Biotech Industry in India is in nascent stage. Compared to market, our own biotech industry is small. It is more service-based and less product- based. Very few entrepreneurs have taken interest into fermentation based units, antibiotics etc. There are early some, who worked in enzymes, biopharmaceuticals, diagnostics. Recent trend of entrepreneurs in India is to establish technology / skill based biotech units rather than capital intensive industries. So, in recent years new biotech companies that are coming up are into Genomics, Bioinformatics, Clinical Research, Drug discovery, Contract Research and Contract Manufacturing. Also low- tech biotech units are found more including biofertilizers, biopesticides, agri-based etc. 50 Entrepreneurs presented here are only Representative of 800 biotech industries existing in India from different biotech waves.
  4. 4. 4 Mr. Ramanbhai Patel Founder Chairman, Zydus Cadila Zydus Cadila develops and manufactures a large range of pharmaceuticals as well as diagnostics, herbal products, skin care products and other OTC products. Now Pankaj Patel son of the founder (Late Mr. Ramanbhai) is CEO of company. Mr. Ramanbhai Patel is First Generation Entrepreneur. At a time when the newly independent nation was heavily dependent on imports of drugs and pharmaceuticals, he had set out to prove that an indigenous company could provide innovative, research-based quality medicines. Cadila Laboratories was founded in 1952 by Ramanbhai Patel (1952–2001). He and his business partner Shri Indravadan Modi were formerly lecturer in the L.M. College of Pharmacy. The company evolved over the next four decades into one of India's established pharmaceutical companies. In 1995 the Patel and Modi families split, with the Modi family's share being moved into a new company called Cadila Pharmaceuticals Ltd. and Cadila Healthcare became the Patel family's holding company. Cadila Healthcare did its IPO on the Bombay Stock Exchange in 2000. In 2001 the company acquired another Indian pharmaceutical company called German Remedies. On June 25, 2007, the company signed an agreement to acquire 100 per cent stake in Brazil's Quimica e Farmaceutica Nikkho do Brasil Ltda (Nikkho) for around 26 million dollars. In 2010, Cadila Pharmaceuticals received a prestigious Wellcome Trust Award under the new "R&D for Affordable Healthcare in India" initiative. Mr. Ramanbhai Patel had published several outstanding research papers and had taken a keen interest in research activities of the group. Today, Zydus Cadila is amongst the top investors in research. Mr. Ramanbhai Patel's contributions in the field of pharmaceutical education were equally noteworthy. The Zydus Research Centre, a state-of-the-art facility which was set up during his lifetime, spearheads the research initiatives of the Zydus group and supports the quest for innovations and excellence in the field of research.
  5. 5. 5 Piyush Palkhiwala, Chairman & Managing Director, Maps Enzymes, Gujarat In 1975, Mr. Piyush Palkhiwala started Maps Industries, a small unit producing alpha amylase for textile desizing application, under the brand name of Palkozyme. In 1995, Mr. Piyush Palkhiwala, chairman of Maps Group was awarded the prestigious "Best Entrepreneur of the Year", by the Rotary International Club. Maps (India) Limited, was incorporated. With over 150 employees, sophisticated production plant and a dedicated R & D centre, company is India‘s largest producer and exporter of enzymes and microorganisms; and a leading player in the global market. Their production facilities have been extended from various enzymes like Amylases, Proteases, Cellulases, Xylanase, Glucoamylase, Pectinase, Catalase, Lipase and Phytase; to different microoganisms using state-of-the-art Solid State and Submerged fermentation from various bacterial and fungal microorganisms. Their enzyme products are used in versatile industries like Textile, Leather, Baking, Alcohol, Brewing, Detergent, Starch, Animal feed and Pulp & Paper. Their microorganisms as products are used in various applications for Effluent treatments, Cleaning and odour control, Waste degradation, Bioaugmentation & Bioremediation and Aquaculture. With a complex product portfolio of 60+ products for more than 10 different industries and a sales network spread across 4 continents in 22 countries, their biotech solutions improve industrial performance and quality while at the same time saving on water, energy, raw materials and waste. Mr. Palkhiwala also serves as an Advisory Committee Member of Gujarat State Biotech Mission (GSBTM)', 'Central Leather Research Institute (CLRI)', Department of Biotechnology (DBT) - Govt. of India', 'Council of Scientific and Industrial Research (CSIR) - Govt. of India' and 'Entrepreneurs Development of India (EDI)‗. Mr. Palkhiwala is an Enzyme Engineer from Indian Institute of Technology (IIT), Delhi.
  6. 6. 6 Mr. L. C. Rathi, Founder, Advanced Enzyme Technologies Ltd. (AETL) (Managing Director) Mr. L. C. Rathi, is the forefather of the Indian Enzyme Industry AETL. Mr. L. C. Rathi pioneered the production of Papain, enzyme derived from papaya fruit, and set- up India's first natural enzyme plant way back in 1958. AETL has carried forth the tradition of his entrepreneurial spirit since 1989. Their extensive biotech experience has led to the development of hundreds of unique enzyme solutions addressing the needs of customers in 25 industries and over 30 countries. Advanced Enzymes is a research driven company with global leadership in the manufacturing of enzymes. The company offers over 400 products from 55 enzymes. Advanced Enzyme Technologies Ltd. comprises of 8 subsidiaries of which, 5 are wholly owned subsidiaries and two are step down subsidiaries. Based on the geographical distribution, they have set up Advanced Enzymes USA, Advanced Enzymes Europe and Advanced Enzymes China to enhance our presence within the respective continents. Advanced Enzymes USA further comprises of two subsidiaries – Advanced Supplementary Technologies Corporation (AST Enzymes) and Cal India Foods International (Specialty Enzymes and Biotechnologies) which are engaged in the research, development and marketing of cutting edge, efficacious and all-natural enzyme solutions of the highest quality. Within India, the subsidiaries focus on different market segments. Their business is primarily divided into two main verticals – Healthcare & Nutrition and Bio-Processing. Healthcare & Nutrition has two distinct divisions i.e. Human Healthcare & Nutrition and Animal Nutrition. Advanced Vital Enzymes Ltd. (Advenza), a sister company, is dedicated to Human Nutrition, while our subsidiary Advanced Bio-Agro Tech Ltd (Bio-Agro) focuses on Animal Nutrition. Bio- Processing also has two distinct divisions i.e. Food Processing and Non-Food Processing. Their subsidiaries, Advanced Bio-Proteins Limited (BioPro) focuses on the Food Processing vertical while Advanced EnzyTech Solutions Ltd (EnzyTech) focuses on the Non-Food Processing industries like textile, pulp & paper, leather, detergents, etc.
  7. 7. 7 Dr. Bala S. Manian Chairman and Founder, Reametrix Inc. Serial Entrepreneur Dr Manian holds more than 30 patents, many of which have resulted in successful commercial products. He is Ph.D. in Mech. Engg. He is expert in the design of electro- optical systems. He has authored several peer-reviewed scientific publications. He has been recognized through numerous awards for contributions as educator, inventor and entrepreneur, including Technical Academy Award in Digital Cinematography by Academy of Motion Pictures, Arts and Sciences in 1999. He is a successful life science entrepreneur transcending three decades. Dr. Manian has been a distinguished contributor to the Silicon Valley entrepreneurial community for the last three decades. At present Dr. Manian is focused on ReaMetrix, which he founded in May of 2003. ReaMetrix is committed to becoming the leading provider of easy-to-use assay solutions that increase reliability and consistency, expand the capabilities of proprietary technology platforms, increase the experimental efficiency and at the same time bring affordable solutions to address needs in India and other developing nations. ReaMetrix, Inc. is a next generation biotechnology company with its primary operations centered in India focused on creating affordable diagnostics. Dr. Manian is a co-founder and director of Quantum Dot Corporation, and a co-founder of SurroMed Corporation, both of which are privately held. He was the founder and Chairman of Biometric Imaging, Inc. which was acquired by Becton Dickinson in February 1999. Before that, Dr. Manian founded both Lumisys and Molecular Dynamics in June 1987 and was their founder chairman and CTO. Lumisys went public in 1995 and later was acquired by Eastman Kodak in December of 2000. Molecular Dynamics went public in 1993, and subsequently was acquired by Amersham in 1998. Dr. Manian founded Digital Optics Corporation in 1980, an optical instrumentation and systems development Company that was acquired by the publicly traded Matrix Corporation in 1984. He is also on Board of Directors of Biocon.
  8. 8. 8 Dr. Cyrus S. Poonawala, Chairman, Serum Institute of India, Pune World's largest makers of pediatric vaccines Dr. Poonawalla graduated from Brihan Maharashtra College of Commerce (BMCC) in 1966. He was awarded a Ph.D. by the Pune University in 1988 for his thesis entitled "Improved Technology in the manufacture of specific Anti-toxins and its socio-economic impact on the Society". Dr. Poonawalla has strong ties with India‘s horse racing and breeding Industry through the family‘s Poonawalla Stud Farms. As per Forbes Mar 2014 rankings, Cyrus Poonawalla's networth is $5.2 Billion and is ranked #10th richest person in India & #286th richest person in the world. He was awarded the Padma Shree for his contribution to the field of medicine, by Government of India in 2005. They set up the venture in 1966 on a 12- acre lot and began producing vaccines. Serum Institute of India launched its first therapeutic anti-tetanus serum within two years, and began producing the anti-tetanus vaccines. In 1989 Serum Institute began the production of its Measles Vaccine M-Vac and within a year Serum Institute became the country's largest vaccine manufacturer. In the 80s India was made self-sufficient for Tetanus, Diphtheria and Whooping Cough vaccines due to the production from Serum Institute. In 1994, Serum Institute got accredited by the World Health Organization (WHO) to export vaccines from India and started supplying high quality vaccines to U.N. Agencies such as UNICEF (United Nations Children's Fund), PAHO (Pan American Health Organization). By 1998 Serum Institute was exporting vaccines to over a 100 countries and by 2000 one out of every two children in the world was vaccinated by a vaccine of Serum Institute of India. Dr. Poonawalla‘s strong belief in "No Compromise with Quality" and willful commitment in "Health for All with affordable Vaccines‖ has today lead Serum Institute to become India‘s leading biotech company producing over a billion doses a year that sell in more than 140 countries around the world.
  9. 9. 9 Dr. Pradip K. Desai Founder Chairman, Span Diagnostics, Surat, Gujarat He is MD (Pathology) from B. J. Medical College, Ahmedabad with brilliant academic career. While practicing as Pathologist at Surat since 1966 onwards, he established Span Diagnostics in 1972 to manufacture and market IVD products with in-house R & D efforts. Dr. Pradip Desai evolved in to a Startup Company as Desai Laboratories in 1972. The goal was to indigenously develop and manufacture a comprehensive range of ready-made diagnostic products needed by various segment of healthcare. In 1976, Span Diagnostics was formed with an emphasis on in-house R&D to develop more and more products, keeping the customer need in to focus and quality under constant vigil. In 1980, company was reorganized as Span Diagnostics Pvt. Ltd. Dr. Pradip Desai has published several research papers and has filed patents in the field of IVD. He has occupied several prestigious positions like Member, Govt. of India‘s Task force on promoting large scale use of Biotechnology (1994-99), Member of task force on immunodiagnostics, Dept. of Biotechnology, Govt. of India (1996-99), Invitee on the State Govt. Panel for promotion of Biotechnology in Gujarat (Since 2005) Today, Span with its high quality products and strong marketing & distribution network across India and abroad is emerging as one of the leading diagnostic companies in the world. Span caters to several different sections of diagnostics like Immunology, Biochemistry, Microbiology, Serology, Histopathology and instrumentation. Products are CE registered as well as certified under ISO 13485:2003 and manufactured in its state-of-the art production facilities. The facility is well equipped to undertake contract manufacturing. Company aims for turnover of Rs. 1000 crores by 2020.
  10. 10. 10 Kiran Muzumdar-Shaw CEO – Biocon India - Chairman & Managing Director Value: Rs 4,843 crore. The country's largest biotech firm spread on an 80-acre campus. She is India's richest woman today. In 2014, she was awarded the Othmer Gold Medal, for outstanding contributions to the progress of science and chemistry. She is on the ‗Financial Times‘ top 50 women in business list. As of 2014, she is listed as the 92nd most powerful woman in the world by Forbes. She worked as a trainee brewer in Carlton and United Breweries, Melbourne and as a trainee maltster at Barrett Brothers and Burston, Australia. She also worked as a technical consultant at Jupiter Breweries Limited, Calcutta and as a technical manager at Standard Maltings Corporation, Baroda between 1975 and 1977. In 1978, she joined Biocon Biochemicals Limited, of Cork, Ireland as a Trainee Manager. In 1978 she started Biocon in the garage of her rented house in Bangalore with a seed capital of Rs. 10,000. Initially, she faced credibility challenges because of her youth, gender and her untested business model. Not only was funding a problem as no bank wanted to lend to her, but she also found it difficult to recruit people for her start-up. With single-minded determination she overcame these challenges only to be confronted with the technological challenges associated with trying to build a biotech business in a country facing infrastructural woes. She spearheaded its evolution from an industrial enzymes manufacturing company to a fully integrated bio-pharmaceutical company with a well-balanced business portfolio of products and a research focus on diabetes, oncology and auto-immune diseases. She also established two subsidiaries: Syngene (1994) to provide development support services as an outsourcing firm for discovery research and Clinigene (2000) to cater to clinical development services. She received an honorary Doctorate of Science in 2004, from her alma mater, Ballarat University, in recognition of her contributions to biotechnology, honorary doctorates from University of Abertay, Dundee, UK (2007), University of Glasgow, UK (2008) and Heriot-Watt University, Edinburgh, UK (2008), honorary doctorate from Davangere University in July 2013.
  11. 11. 11 Mr. Arunachalam Muthu, Managing Director Saf Yeast Co Pvt. Ltd. (SYCPL) Muthu is also credited with personally transforming approximately 2,500 bakeries in Mumbai from using hops to yeast. In fact, this also made him confident in effectively dealing with the bakery segment and marketing his yeast. Yeast production in India was virgin at that time and Muthu was marketing baker‘s yeast at Shaw Wallace & Co. over two decades ago. Muthu, a mechanical engineer from Guindy University of Madras (now Chennai) was with Shaw Wallace and Co for 16 years i.e. from 1965 - 1980. He is credited with setting up the Indian Yeast Factory and the Skol Brewery at Uran and subsequently took up the marketing of yeast. Saf Yeast Co. Pvt. Ltd. was set up in the year 1981 by Arunachalam Muthu in technical and financial collaboration with M/s Lesaffre et Cie of France - one of the world‘s largest producers of bakers‘ yeast with factories in 54 countries. As for the yeast manufacturing process at SYCPL, the cultured yeast cell comes in test tubes from Lesaffre et Cie, France. It is then developed/multiplied from the test tube to a beaker and then to a flask to a big vessel to a big fermentor. SYCPL cultivates its yeast under expert supervision at the company‘s state-of-the-art manufacturing units at Chiplun, Maharashtra and Sandila, Uttar Pradesh. The entire process from test tube to large volume takes approximately five days. And if the yeast is stored at four degree centigrade, it can be kept for a month. Another way is to freeze it which allows the yeast to be stored for months together, but Muthu prefers the first approach. The expertise leveraged by their French partners, state-of-the-art technology, experienced, qualified staff apart from an extensive distribution network and efficient marketing is what makes SAF Yeast beyond competition. Saf Yeast Co. Pvt. Ltd. is today the leader in the field relating to the baker‘s yeast market in India. The company has 24 branches and staff strength of 570. Helios Food Additives Pvt Ltd was set up by Muthu in the year 1984 for the production of emulsifiers, bread improvers, cake improvers, baking powder etc and is the pioneer in these products that were hitherto unknown in the bakery trade. The Muthu family wholly owns this company.
  12. 12. 12 K. I. Varaprasad REDDY, Founder, Shantha Biotechnics, Hyderabad Value: Rs 725 crore* By producing India's first genetically-engineered Hepatitis-B vaccine in his Hyderabad-based laboratory, Reddy brought down its price from Rs 800 per dose to Rs 40. He is B. E. in Electronics (Andhra University), MBA (Osmania University). 1972-77 - He worked as Research scientist for Defense Electronics Research Laboratories, Hyderabad. 1977-1985 - He worked in APIDC (Andhra Pradesh Industrial Development Corporation). During that period he assisted in promoting number of industries & assisted entrepreneurs in their project implementation. He established his own company in 1992 to produce cost-effective drugs. He has received many business awards and recognitions such as -  Ernst & Young – Entrepreneur of the Year, 2000 for healthcare and life sciences  BioSpectrum Person of the Year award for 2007 for ―pioneering a biotech wave‖  Sri Venkateswara University, Tirupati – Honorary Doctorate (2005)  National Technology Award – for successful commercialization of Scientific Products – In 1999 for SHANVAC-B and in 2003 for SHANFERON  DSIR – (Dept. of Scientific Industrial Research, Govt. of India) Award – for best R& D efforts in industry – In 1998 for SHANVAC-B and in 2003 for SHANFERON  DBT – (Dept. of Biotechnology) Award – for SHANPOIETIN (2005)  Federation of AP Chambers of Commerce & Industry Awards  Best Exporter (1986)  Best Marketing Efforts (1999)  Best New Product Innovation Award for SHANFERON (2004)  Best Technology Development in R&D award for SHANKINASE (2005) He received Padma Bhushan in 2005 from Govt. of India.
  13. 13. 13 Dr. Krishna M. Ella, Bharat Biotech International Ltd., Hyderabad Scientist-turned-serial entrepreneur Krishna M Ella has shown that Indian R&D can be driven by society‘s needs, not western markets. Alumnus of University of Wisconsin-Madison, Ella taught at Medical University of South Carolina at Charleston after completing his PhD. He wanted to return to India in the early 1990s. In 1994, he was approached by a large company that wanted to hire him as its R&D chief. However, Ella discovered that research & development (R&D) at that company was seen as just a tax-saving activity. Ella finally landed in India in 1996. His quest turned him into a bio-entrepreneur, which led to the birth of Bharat Biotech International (BBIL). Today, it is the largest producer of hepatitis- B vaccines in the world, with a capacity to manufacture 100 million doses a year. Started with an investment of Rs 12.5 crore, BBIL‘s turnover in 2010 stood at Rs 300 crore. Ella envisages a topline of Rs 2,000 crore in five years. Ella, set up Biovet at a cost of Rs 100 crore in 2005 to develop and manufacture products like foot & mouth disease vaccines. It is Asia‘s first and the world‘s second bio-safety level 4 (BSL-4) manufacturing facility. Ella is building the Konark Knowledge Park in Bhubaneswar as a public-private partnership (PPP). Work on the project began in 2009 and will promote biotechnology, pharmaceutical and information technology industries. Investment in the park will be around Rs 100 crore. Ella has also set up Innova Agri Bio Park in Bangalore at a cost of around Rs 17 crore. Spread over 90 acres, again as a PPP project, it aims to help farmers and consumers. It has a Gamma irradiation facility that not only increases the shelf-life of farmers‘ produce, but also helps overcome quarantine barriers in international trade. Ella was also instrumental in setting up a biotech knowledge park in Hyderabad that culminated in Genome Valley. The project emerged from a presentation Ella made to then chief minister N Chandrababu Naidu, who acted on his recommendation to set up such a park. BBIL was the first to come up in Genome Valley, which currently has over 100 biotech units.
  14. 14. 14 Ms. Anuradha Acharya, Founder & CEO (2000-2013) Ocimum Biosolutions Currently CEO at Mapmygenome.in, YGL- WEF, Hyderabad, India CEO at Gene Logic, An Ocimum Biosolutions Company. Consultant at SEI Information. Ms. Acharya has an MS in Management Information systems (University of Illinois) at Chicago. She also has an MS in Physics from the same school. She has a Bachelors and Masters from the Indian Institute of Technology at Kharagpur. She worked as an IT professional for six years, before founding Ocimum Biosolutions. She is regarded as incredible networker. While she was pursuing her MS she joined companies like Mantiss Information and SEI Information Technology in Chicago to learn the tricks of running an organization. Ocimum Biosolutions is a life sciences R&D enabling company with three focus areas, BioIT, Microarrays and Research services. The Microarray division of Ocimum has been recently acquired from MWG Biotech. These include Catalog ―OciChip‖, Custom ―OciChip‖ and microarray services. Prior to founding Ocimum, Acharya held positions in a consulting company called SEI Information and a telecommunications software company called Mantiss Information which has since been acquired by Dynegy Corporation. She is also a board member for the Association of Biotech Enterprises, is on the Advisory board for the Action for India and on the board of mentors at IvyCap Ventures. The Maryland-based company Gene Logic's Genomics division was acquired by Ocimum in 2007 and in 2012 Ocimum sold a portion of the business (BioRepository), to Transgenomics and moved the rest of the business to India. Awards & Recognition To name some, amongst many -  She was named by Red Herring Magazine to the list of 25 Tech Titans under 35 in 2006.  She has also received the Entrepreneur of the year award by Biospectrum magazine.  Asia Life Science Innovators Award in 2008.  She has been honoured as a 2011 Young Global Leader by the World Economic Forum.
  15. 15. 15 Villoo Morwalla Patel CEO, MD, Avesthagen Gengraine Value: Rs 600 crore* A scientist-turned- entrepreneur, Patel has focused on innovative research and biotech services in pharma and agriculture. Her Bangalore- based company has 49 patent applications. She is M. Sc. (Bombay University) and Ph. D. (Pasteur Institute, France) Post-doctoral work (University of Ghent in Belgium). On her return to India, she established herself as an independent scientist and principal investigator working from the National Center for Biological Sciences (NCBS) with funding from the Rockefeller Foundation and subsequently at the University of Agricultural Sciences (UAS) in Bangalore with a grant from IFCPAR, the Indo-French Centre for the Promotion of Advanced Research. Working with scientists from all around the world really sparked off her entrepreneurial spirit. She then returned to India with an idea rooted in her mind – to create a platform that would bridge Academia and Industry. Thus was the seed sown that would give birth, a few years later, to Avesthagen. ICICI Ventures, Global Trust Bank and Tata Industries invested 8 crores in the company, which had now settled in its new laboratories in the International Technology Park at Whitefield. This was only the beginning. Since then Villoo has ceaselessly worked to build the company and raised significant international funding, attracting foreign investors and partners who saw a potential in the young Indian biotech sector and particularly in this fast growing company with its promise of innovation in predictive, preventive, personalized healthcare and environment- adjusted crops and nutritionally-enhanced seeds for agriculture. Avesthagen now has 650 employees. Foreign investment stands at 31% today. Today, the company has a portfolio of 350 patents filed, it continues to build and intensify its intellectual property through product commercialization. Dr. Patel has built a ―Business of Science‖ and developed a new model of ―Science of Business‖ to deliver products from ideas.
  16. 16. 16 Dr Mugasimangalam C Raja President, Founder and CEO, Genotypic Technology Dr Mugasimangalam C Raja, holds a Masters & Ph.D in Biotechnology from Madurai Kamaraj University, Madurai, Tamil Nadu. His research career post-Ph.D, involved developing techniques for DNA sequencing (Weizmann Institute, Israel) and mutating specificity of restriction enzymes (Sidney Kimmel Cancer Center, San Diego, USA). Dr Raja worked as a Human Genome Project Scientist at the US Government's Argonne National Lab Argonne II, USA. He has developed two novel methods for constructing cDNA microarrays during his stint at QBI Enterprises Ltd., Israel. His accomplishments include several peer reviewed research articles, inventions reports, and several US patents. Dr Sudha Narayana Rao Co Founder and Executive Director Dr Sudha Narayana Rao holds a Ph.D. in Biotechnology from Madurai Kamaraj University, Madurai. She has completed her Post-doctoral research in Neurobiology at the Medical Center in Cornell University, New York and subsequently worked as consultant Neurobiologist for QBI Enterprises, Israel. She has to her credit several publications in peer-reviewed journals. Genotypic Technology Company was set up in 1998 and it started business operations in 2000. Genotypic Technology is the World‘s first company to be Agilent technologies Certified Service Provider for three major microarray applications and India's first Certified Service Provider for Ion Torrent PGM. Genotypic is the First Genomics Company to run its business processes on SAP ByD. An ISO 9001: 2008 accredited company with 11,000 square feet genomics facility in Bangalore, India. Their high throughput facilities enable them to provide Microarray, Next Generation Sequencing and Bioinformatics services and solutions. Genotypic has a rich history of clientele both in industry and in academia. Clients worldwide make use of Genotypic‘s services for a range of services from protocol optimization, probe designing, array layouts, project designing, and nucleic acid analysis to in-depth analysis. Work done at Genotypic is acknowledged and cited in over 150 publications.
  17. 17. 17 Swati Piramal, Vice Chairperson, Nicholas Piramal Value: Rs 120 crore* The Mumbai-based firm is involved in a range of biotech services, including diagnostics, clinical trials, gene testing, lab services and drugs. Piramal Enterprises is a multinational, with global manufacturing operations and supplies medicines to over a 100 countries. Dr. Swati Piramal M.B.B.S. (Mumbai University) is one of India's leading scientists and industrialists, involved in healthcare, focusing on public health and innovation. Her contributions in innovations in new medicines and public health services have touched thousands of lives. Dr. Swati Piramal leads a team of scientists in cancer, diabetes, inflammation and infectious disease research, with a portfolio of over 200 international patents, and 14 new drugs. Apart from many other awards, On April 2012, Dr. Swati Piramal received the Padma Shri.  She currently serves on the Dean‘s Advisory Board of both the Harvard School of Public Health and the Harvard Business School.  Board Positions in healthcare, financial services, manufacturing and service companies.  She serves on the Boards of Indian and International Academic institutions such as IIT Bombay, and Harvard University. She has also served UPenn.  Helped create the foundation for effective public policy and governance that encourages private and public institutions to work together, to solve problems in healthcare and business.  She also serves on government public policy committees for trade, planning, environment, arts, women‘s entrepreneurship, national integration, and regional development.  She has been the first woman President of India‘s Apex Chamber of Commerce, ASSOCHAM, in 90 years.  Worked in the prevention of chronic diseases like Diabetes, Arthritis, and Heart Disease.  Founder of the Gopikrishna Piramal Hospital in Mumbai  Launched public health campaigns against chronic disease, osteoporosis, malaria, TB, epilepsy and polio.
  18. 18. 18 Rajesh Jain, Jt. Managing Director, Panacea Biotec Ltd, New Delhi Company was started in 1984. Value: Rs 260 crore. Exporting genetically engineered products like insulin and anthrax vaccines, the Delhi-based firm is among India's fastest growing biotech companies and is considered a one-stop shop. Net turnover of company was Rs 831.55 crore in 2008-09. The total biotech revenue stood at Rs 597.14 crore as against Rs 678.41 crore previous year, while the vaccine segment registered net revenue of Rs 547 crore as compared to Rs 636 crore in 2007-08. In July 2008, Panacea Biotec received WHO pre-qualification for its fully liquid innovative combination pentavalent vaccine, Easy five, which resists against five deadly infectious diseases (DTwP+ Hep B+ Hib) of early childhood. EasyFive (Pentavalent) vaccine is available in different markets with antigens used from different sources. Panacea had earlier received pre- qualification by WHO for two other combination vaccines, EasyFour (DTP + Hib) and Ecovac (DTP + Hep B). In a notification, WHO has advised the UN procuring agencies regarding the acceptability of these vaccines worldwide. Panacea Biotec is already a pre-qualified supplier of OPV and hepatitis-B vaccines to UN agencies. He is amongst Top 40 Global most influential persons as per the list put together by an internationally reputed organization World Pharmaceutical Frontiers published in SPG Media, London. His commitment and actions towards making affordable vaccines for mass population across the globe were well appreciated and valued by GAVI alliance and Bill & Melinda Gates Foundation at pledge conference at London in June 2011. As a Chairman of CII National Committee on Biotechnology for second consecutive year Financial Year in 2012-13, he has been driving numerous initiatives for providing better business and regulated environment for nurturing Biotechnology industry in India.
  19. 19. 19 Dr BVLS Prasad Helix Genomics Pvt. Ltd. (HGPL) Hyderabad, India Helix Genomics Pvt. Ltd. (HGPL), India is a university startup led by the 1st generation entrepreneurs and is located at Genome Valley, Hyderabad, Andhra Pradesh, India and at London. HGPL Vision is to emerge into a global product and services major in Bio- computational Research and Analysis. The objective is to interface HGPL technology to create cost effective and efficient products and services in the areas of Genomics, Proteomics, Structural Biology and Bio- computational research & analysis. HGPL technologies will facilitate faster and effective R&D initiatives across Biotech/ Pharmaceutical industries and academia. The company is focusing on areas such as Sequence and Structural Genomics, Disease gene discovery & Bio-Nano machine design, Homology modeling and Drug discovery. The company's competency lies in algorithm-oriented biological programming and providing solutions for the most complex biological queries. It utilizes its in- depth biological and disease knowledge to discover novel biological pathways of diseases and for drug target identification. It uses in-house technologies, and takes up custom design from novel algorithms to specific molecular targets in drug discovery, industrial enzymes and protein engineering. Helix also undertakes services emerging from the vast explosion of biological data like Micro Array data analysis and provides efficient answers to the biological query. Helix's in-house technologies developed and patented in USA/ EU include – (i) Biological Operating System (BOS) which is 1st of its kind Object Oriented Biological Programming Environment used in biological data analysis (ii) Macromolecule Architectural Component System (MACS), a novel methodology for engineering new targets, sensitive regions of functional importance, nano-molecule design and development (iii) Novel Oncogene Database (OncoBase) which has used novel genetic parameters to develop comprehensive oncological database of biological significance for new drug target identifications.
  20. 20. 20 Dr. Shama Bhat Founder, Chairman and Managing Director, Bhat Laboratories The urge of doing something different than working as a professor or a scientist made Dr Bhat come to India and give wings to his entrepreneurial dreams. An alumnus of Kasturba Medical College, Manipal and the Indian Institute of Science, Bangalore, trained at the University of Connecticut Health Center, Farmington, US. Dr Bhat worked as the faculty at the Neurology Department, University of Pennsylvania, US, from 1983 to 1994. His discovery of Galactosyl Ceramide, as an alternative receptor for HIV in neural cells, won him both universal acclaim as well as the undivided attention of global scientific circles. He has over 40 publications to his credit and is a recipient of the prestigious Ranbaxy Award. Bhat Biotech India was established in 1994. Bhat Bio-Tech started with pregnancy test kit in 1996 and today, it has more than 100 kits for diagnosis of many diseases and conditions. The company that started with a handful of people, today under the leadership of Dr Bhat has more than 200 working people and more than 300 people benefited indirectly. In response to the recent epidemic of chikungunya and swine flu, Bhat Bio-Tech worked round-the-clock to bring out the diagnostic kit for chikungunya in about six months time. Similarly, when H1N1 was a national health threat, the company worked hard to bring a molecular level detection kit in record time, now waiting for the license from the drug authorities. At present, Bhat Bio-Tech is working on molecular diagnostics, pharmacogenomics, lab-on-a-chip for several parameters, diagnostics for veterinary, agriculture and food safety. The company is focusing on both protein-based and molecular biological methods for the development of diagnostic kits. Dr. Bhat believes that despite pharmacogenomics, the so-called personal medicine, the major hospitals and big diagnostic centers will continue to use the automated machines for the diagnosis.
  21. 21. 21 Ramakrishna V. Modali – Founder, President Bioserve Biotechnologies (I) Pvt. Ltd., Hyderabad Since BioServe's inception in 1989, Rama spearheaded efforts to develop and provide advanced molecular biology services to pharmaceutical, academic and government institutions. With more than 30 years experience in molecular biology, Rama continues to guide BioServe's successful growth, international expansion and provision of cutting-edge scientific applications to enhance our customers' research. Prior to founding BioServe, Rama worked as a molecular biologist at the National Institutes of Health and National Cancer Institute. He has over 32 peer reviewed research publications. BioServe India is a state-of-the-art genomics services provider and molecular kit manufacturer serving both the research and clinical markets. Contract Research Organization, First Indian DNA Synthesis Company. Some of the BioServe India customers include Dr. Reddy‘s Laboratory, Indian Institute of Science Education & Research and the Centre for Cellular and Molecular Biology (CCMB). BioServe's Global BioRepository provides leading academic and industry researchers with access to over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients on four continents. Utilizing BioServe's preclinical molecular services, researchers can identify genetic markers, validate drug targets and correlate clinical and molecular data to accelerate the development of new and safer drugs. BioServe's customers include nearly every major pharmaceutical and Biotechnology Company, as well as top industry, academic, and government research institutions. BioServe has corporate headquarters in Beltsville, Maryland and Hyderabad, India.
  22. 22. 22 Dr. Muhammed Majeed Founder and Managing Director, Sami Labs Limited Established in 1991. Now it has 500 people working in it. Dr. Majeed received awards from several Indian American groups for his enterprising work and progress. He also received the 1996 Entrepreneur of the year award by the National Federation of Asian Americans. The aspiration to dream and the conviction to follow their dreams is what sets apart the extraordinary from the ordinary. Dr Muhammed Majeed, introduced to the Americans that Ayurveda from India can act as a complete curative to their various ailments. The persistent efforts by Dr Majeed in the early nineties in the field of Ayurveda did reap benefits among the Americans. They started recognizing the potential of Ayurveda and termed it the Alternative medicine. By 2000 it became popular as the Complementary medicine and now it is called as the Integrated medicine. After taking B. Pharm. from Trivandrum Medical College, Dr Majeed went to US in 1975 to take MS in Pharmacy and PhD in Industrial Pharmacy. He worked with some of the major pharmaceutical companies like Pfizer which earned him valuable experience in the latest technology in drug formulations. From here, he chose to establish himself as an entrepreneur by integrating technology with Ayurveda. It was the beginning of a new success story. He came out with new drugs with their actives taken from the herbs. Dr Majeed also researched into the medicinal values of some plants which are not mentioned even in the Ayurvedic texts. For instance Boswellin is a drug extracted from Boswellia Serrata (Kunthirukkam in Malayalam). It is an anti-inflammatory agent. Tetrahydro Curcuminoids is another product derived from turmeric. What makes Curcuminoids different is that it is turmeric without the characteristic yellow colour. It can be used as a cosmetic as well as an anti oxidant. Gugulipid, Bioperine, Citrin and Petro Selenic Acid (derived from Coriander oil) are some other products which Sami Labs markets globally. The manufacturing of the standardized herbal extracts happens in India with US as its major market for these standardized products.
  23. 23. 23 VIJAY CHANDRU, Ph.D Co-founder, Chairman and CEO Strand Life Sciences (Strand Genomics) Company was founded in the year 2000 by 4 computer science faculty of Indian Institute of Science, V Vinay, Swami Manohar, Vijay Chandru and Ramesh Hariharan. One of few companies in the world with the full complement of multi-disciplinary expertise needed for modern data-driven approaches to genomics research and its clinical applications. It has a team of over 200 scientists and engineers from some of the world's best academic institutions: Indian Institutes of Technology, Indian Institute of Science, Massachusetts Institute of Technology, Johns Hopkins University, Oxford University, New York University, University of Pennsylvania, Fred Hutchinson Cancer Center, National Institutes of Health, Buck Institute, University of California, Berkeley, University of Minnesota, Rockefeller Institute, University of Gottingen etc. Under one roof, they work together on software engineering, data mining, bioinformatics, assay development, laboratory automation, sequencing-based diagnostics, and clinical delivery. Founding theme was “Algorithms for Life”. Since then, they have established a strong portfolio of products for biological systems research and for diagnosis and treatment of disease. Their products are fueled by a vast and unique collection of technology and expertise. Over 2000 scientific laboratories across the world and over 100 hospitals are the clients. They have now entered an exciting new era of guiding medical decisions using insights into the molecular world of genomes, genes and proteins and have been able to touch people's lives in the process. Their new theme is "New Generation Healthcare". UTI Ventures gave in $1.3 million a year after company was founded, and, in 2002, WestBridge Capital Partners invested $1.9 million. However, things changed dramatically in 2013, when Strand got $10 million from San Francisco-based financial firm Burrill & Co. Their vision is to find newer and better ways to deliver this information to researchers, doctors and patients.
  24. 24. 24 K. V. Subrahmanyam President & CEO, Reliance Life Sciences K.V. Subramaniam is a Chemical Engineer from Madras University, an MBA from the Indian Institute of Management, Ahmadabad and a Chartered Financial Analyst. In a career spanning 28 years with the Reliance Group and Indian Petrochemicals Corporation Ltd., he has been responsible for several functions – from corporate business development, corporate planning, project management and economic analysis to marketing; in a range of businesses – from petrochemicals, energy, alternative energy, infrastructure, insurance, education, health care and agriculture to life sciences. K.V. Subramaniam is the President and CEO of Reliance Life Sciences, a research- driven organization developing business opportunities in biopharmaceuticals, pharmaceuticals, clinical research services, biofuels, regenerative medicine, molecular medicine, plant biotechnology and industrial biotechnology. Reliance Life Sciences is part of the Reliance Group of companies in India, with group revenues of US$ 35 billion in the energy and materials value chain. Mr. Subrahmanyam has been associated with Reliance Life Sciences from its very inception till date, and have been responsible for building the initiative over the last 10 years from scratch – through formulating its vision, developing strategies, hiring people, engaging teams, creating programmes, designing the organization, building facilities, instituting systems, processes and policies and motivating performance. K.V. Subramaniam serves on the Board of the Institute of Chartered Financial Analysts of India, ICFAI University, GeneMedix plc UK, HN Hospital, Mumbai and the Dhirubhai Ambani International School, Mumbai.
  25. 25. 25 K. K. Narayanan Managing Director, Metahelix Life Sciences, Bangalore Mr. K. K. Narayanan started Metahelix along with four other scientists in 2001. He is B.Sc in Agriculture, Masters degree in Plant Breeding and Genetics from the Kerala Agricultural University, Ph.D. in Plant Breeding and Genetics from Tamil Nadu Agricultural University, carried out post- doctoral research at the Department of Biological Sciences, Stanford University under a Rockefeller. Dr KK Narayanan's passion for agriculture and good entrepreneurial skills has resulted in Metahelix gaining a significant traction in the agribiotech field. At the SPIC Science Foundation, he initially worked as a scientist, a senior scientist and then as group leader. A bigger opportunity came knocking towards the end of 1998 and he joined the Monsanto Research Centre in Bangalore as programme leader for crop transformation and functional genomics. Always having wanted to do something on his own, Dr Narayanan's wide exposure to topics global in nature, extensive travel and networking with experts in the field of agriculture only strengthened his conviction that technology exchange that had been happening at Monsanto, could be used profitably in India. While Dr KK Narayanan was still working at Monsanto, his friend and colleague Dr Gautham Nadig who had already come out of the organization, did the groundwork to set the ball rolling for the establishment of their company. Soon Dr Narayanan and Gautham Nadig along with three other scientist friends - Ganesh Kishore, Himadri Pakrasi and Suri Venkatachalam, who all had the common vision of harnessing technology to create societal value, joined hands and thus was born Metahelix. They were lucky to find an angel investor in co-founder of software major Infosys, NS Raghavan who offered them Rs 6.5 crore in venture capital. With the availability of funds, they moved to a bigger place in VV Puram in South Bangalore. Metahelix also plans to start production of protein biologicals, diagnostics and parallely launch marketing and sales operations for protein biologicals. It is also looking at first round of investment to facilitate further expansion.
  26. 26. 26 A V Rama Rao Founder, Chairman & Managing Director, Avra Laboratories Private Limited Rama Rao is an eminent Indian scientist with over 35 years experience in research and leadership. He was the former Director of the Indian Institute of Chemical Technology (IICT) – a premier chemical research organization within the Council of Scientific and Industrial Research (CSIR), Government of India. His work on the isolation, structure elucidation of natural products and the syntheses of complex natural products is described in 262 research papers and 30 patents. He developed over 50 drug technologies that have been commercialized by the pharmaceutical industry. He guided 109 Ph. D students in organic synthesis. He was bestowed with the title of Padmashri by the President of India in 1991. Founded in 1995, Avra Laboratories Private Limited is amongst the first companies in India to focus on: Providing high-end contract research, Custom synthesis of complex chemicals, Manufacturing of niche intermediates and APIs covering various therapeutic areas including oncology. The Company has an experienced and reputed scientific leadership team with strong client relationships with both big pharma and biotech companies. Its subsidiary – Avra Synthesis Private Limited is engaged in providing high quality, pre- tested laboratory chemicals and reagents to various research organizations, companies and academic institutions. The company has four R&D and manufacturing facilities (including one facility owned by Avra Synthesis) with three located in Hyderabad and one site in Visakhapatnam, India. The facilities are certified with ISO 9001 and the company follows cGLP and cGMP practices. It is also in the process of getting its oncology block approved by USFDA. Avra Synthesis is part of Avra Group of companies started by Dr. A. V. Rama Rao an organic chemistry exponent of international repute. Avra Laboratories is a pioneer in initiating contract research in India. Avra Synthesis offers a wide range of Fine chemicals and solvents of Laboratory Reagent (LR) Grade catering to the requirement of various organizations involved in research and contract manufacturing.
  27. 27. 27 Sandeep Saxena, CEO and founder Acton Biotech (India) Pvt Ltd. Pune Business - Diagnostics Always aspired to be an entrepreneur in the business of life sciences and has his own start-up business. Sandeep is a self confessed risk lover. He took up the entrepreneurial journey because in comparison to a normal job it offered so much more. He says ―A job was too easy for me. There was no challenge, no risk, no thrill, no satisfaction and little learning. People had told me the setting up and building a venture is risky, challenging and there is a lot of learning. I wanted to experience all this on my own.‖ He joined Nirma University for an MBA course, the university later accepted his business proposal for the start-up, Acton Biotech. Working on cancer drugs and is educating doctors about the efficacy of different types of drugs on different types of genes. Acton has 10 collection centers all over the country. Unlike any other diagnostic company, which tests blood samples as per the requirements of the doctor or the patient, Acton collects blood samples from all over the country and then extracts the single nucleotide polymorphism (SNP) in the gene and checks the enzymes responsible for the metabolism of drugs for the disorder or disease and prescribes drugs accordingly. ―In a case like oncology, if you look at drugs for complex diseases like cancer they work only on 20 percent of the population on an average. The difference in efficacy is because the metabolism rate differs from person to person. Currently the company is working on genotype efficacies for oncology. Future plans are to move into other segments like cardiology, diabetes and asthama, to achieve next year's target revenue of Rs one crore.
  28. 28. 28 Dr. Rama Mukerjee Ara healthcare Pvt. Ltd. Gurgaon Started in 2007 Number of Employees – 48 Dr. Rama Mukherjee, PhD has devoted thirty-seven years of her career in carrying out research in understanding molecular pathology and in developing products for the treatment of human diseases. AraHealthcare was founded in 2003 and became operational in 2008. Research & Development of Biomolecules is done with focus on humanized antibodies along with molecular diagnostic services. Company is focused on developing novel biological entities and providing molecular diagnostic services for genetic and infectious diseases. Dr Rama Mukerjee has been the brain behind Dabur Research for quite a few years where she headed the R&D unit. She is now all set to synergize her scientific capabilities coupled with entrepreneurial spirit. Ara Healthcare is based in Gurgaon. A team of six scientists from Dabur works and recruitment is on to ensure that Ara is 30-people strong soon. They already have three molecules from Dabur (for cancer) for further development out of which two are NMEs and the third is a biological entity. It currently has facilities and labs for molecular biology, protein chemistry, protein purification, PCR and a preclinical analytical support lab. The company also received funding under the SBIRI scheme by DBT for developing three recombinant proteins and has close to 50 people now working in various capacities. The company is also developing an array of sophisticated and sensitive diagnostic assays for early disease detection and therapy monitoring. Gen-X Diagnostics is a unit of ARA Healthcare Pvt. Ltd. founded by leading applied research scientist Dr. Rama Mukherjee. Gen-X specializes in the field of molecular diagnostics, focusing on the development of genetic, biological and molecular diagnostic services.
  29. 29. 29 Supreet Deshpande CEO, Vlife Sciences Technologies Pvt. Ltd, Novalead Pharma, Pune Started in 2007, Business: Drug Discovery Research Supreet is the visionary behind VLife and is the architect of VLife's technology platform. He received the prestigious BioSpectrumAsia Entrepreneur of the Year 2011 Award. VLife offers solutions for Computer Aided Drug and Molecular Discovery. Their predictive technologies find application in molecular level modeling, simulation, analysis, visualization and interpretation. The genesis of Novalead Pharma is yet another example of a research division being hived out. Towards the end of 2007 Pune-based drug discovery Software Company, VLife Sciences divested its research arm and named it as Novalead Pharma. Supreet Deshpande, is CEO and the brainchild behind Novalead Initial investment of one and a half crore rupees, came from personal funding and remaining was savings of founders and Angel investors. The Series - A venture capital investment was raised in April, 2006 through the Kotak Mahindra - Private Equity Group. As of now, there is a big investor interested in investing, whom Deshpande did not want to name. Revenue churning will only happen after two years when the licensing of Intellectual property will kick start after human validation will be complete. At present the lead compound for Diabetic Foot Ulcer is in process. By 2011, it should be out-licensed, with the deal touching around $400-700 million mark. The Co-Founder and COO, Atul Aslekar again has the main responsibility to lead technology development and sourcing to continuously improve on NovaLead drug discovery process. In the avenue of technology, Novalead has come up with virtual screening technologies like VLifeAmadeus screening platform and VLifeBiblica knowledge compendium (developed along with VLife Sciences).
  30. 30. 30 Dr. Shesheer Kumar RAS Lifesciences, Hyderabad MD & CEO Business – Molecular Diagnostics Started in 2008, Number of Employees - 15 RAS Lifesciences is determined to deliver the best and cost-effective solutions for healthcare for private and public biotech sectors. Dr. Shesheer Kumar is the founder Director of RAS Lifesciences. He was awarded a PhD by Osmania Univeristy, Hyderabad in Genetics. Prior to establishing RAS Life sciences, he worked as a Scientist at Shanta Biotechnics, Hyderabad. He was actively engaged in development of recombinant clones for the production of Human Insulin, Streptokinase, EPO, Interferon etc . Dr. Kumar was also engaged in development of HCV antigen based kit which required cloning, expression & purification of HCV proteins Core, NS3, NS4 and NS5 genes of Indian isolate in E coli. He held the post of Director at Anoop Labs, Allahabad and instrumental in setting up and management of Molecular Diagnostic Lab. He has several publications to his credit in various National & international Journals. Dr Shesheer Kumar, MD, RAS Life sciences believes “Dream until your dream comes true”. With the changing scene in the country, RAS Lifesciences is also involved in planning their priorities, analyze the research capabilities and foresee the need of the service sector in terms of biotech products. The startup is working on molecular diagnostics and is engaged in design, development and commercialization of cost- effective screening system for various infections, genetic diseases and various cancers. The company is also working as consultants in biotechnology providing personalized solutions for industries, academic biotechnology teams, individual investigators and investors. RAS Lifesciences carries out research projects in the area of molecular diagnostics, which includes identification of novel markers for detection of cancer, cost- effective assays for infectious diseases and development of Real-Time PCR based quantitation assays. RAS would be starting its cell culture facility, manufacturing and marketing of diagnostic kits and production of industrial enzymes. India-based RAS Life Sciences has come a long way from being a $50,000 start-up in 2006 to becoming a part of a two-billion- dollar French diagnostic company.
  31. 31. 31 P Gopal Krishnan, MD KARD Scientific India, Pune KARD Scientific offers its superior contract research service at reasonable pricing with world class laboratory facilities and up-to- date regulatory standards. Focus, is preclinical research in various in vivo disease models. Many of their research protocols are now the industry standard. KARD Scientific Inc. is a leading pharmaceutical research company specializing in preclinical contract research services. They assist clients through all stages of drug discovery and development from synthesis and formulation, to protocol development and FDA submission. Over the years, KARD has played a key role in the launch of some of the most important drugs in oncology. They also provide laboratory testing services to the environmental, food and nutraceutical supplement industries. Company offers high quality, efficient, cost effective pre-clinical services in cancer, neurological, inflammation, arthritis and other disease models. It combines knowledge from their network of industry experts and impeccable service to achieve your IND goals. Their track record speaks for itself. Since 2002 their customers have achieved the approvals for drugs for cancer, diabetic wound healing, neurological disorders, antiviral. This company assists its customers in study of design and methods for screening of their molecules so that they obtain maximum efficacy. Technicians and lead researchers of company have many years of experience of respective fields. Company carries out studies in oncology, neurology, inflammation, surgical models, mutation models, in vitro models, invasion models, biomarkers etc.
  32. 32. 32 Naveen Kulkarni, Founder, CEO Polyclone BioServices, Bangalore Naveen Kulkarni has a Masters in Applied Science (Life Science) from Queensland University of Technology Brisbane, Australia. Polyclone Bioservices, which started operations in May 2005 with investments from founders and close associates, as a bioinformatics and consulting services company, was amongst the earliest companies in India to incubate its lab from a university laboratory. It addresses the research challenges in drug discovery by synergistically combining in silico & in vitro approaches. The company has presence in Europe and USA. It is an integrated biology company with expertise in molecular, cell & computational biology catering to the bio-pharma & healthcare industries. For bio-pharma companies we provide in silico & in vitro solutions that facilitate nucleic acid enzyme modifications and small molecule research. For healthcare providers they provide technology support for cell culture studies and molecular diagnostics. Naveen Kulkarni comes with over 15 years of scientific & entrepreneurial experience in the drug discovery industry across the USA, Australia and India. Prior to founding Polyclone, he served as the director of business development at Philips Research, where he was associated with a portfolio of opportunities for new business creation in healthcare and energy. In his previous roles, he has risen through the ranks - from being a bench worker at an Australian research institute to heading the strategic business unit of an American drug discovery informatics company. He has conceptualized and developed novel solutions for accelerating drug discovery and directed teams consisting of experts from different domains including chemistry, proteomics and systems biology. He has been instrumental in conceiving new ideas that are the basis for Polyclone's patent portfolio.
  33. 33. 33 Dr. Raghavendra Gaikaiwari Chairman and Managing Director, Hi Tech Biosciences India Ltd. Mr. R.P. Gaikaiwari, an M. Tech. in Biotechnology from IIT Kharagpur, started HiTech Bio Laboratories, to develop technologies in biotechnology and biochemistry. The firm was quite small when they approached TIFAC for support. During the course of the project, the company has grown into a contract Research Lab. in Biotech in the last two years. The success of the Gallic acid project has given them the confidence & the resources. He started in 1994, as Hi Tech Bio Laboratories. Hi Tech Biosciences India Ltd. (formerly known as Hi Tech Bio Laboratories) is a bio- science company. It is engaged in contract research and contact manufacturing of pharmaceutical, biotechnology, drug discovery and agricultural companies. Company has 20,000 sq. ft. state-of-art R & D facility in Pune. Activities of company include Contract manufacturing of Steroid & Other Bio-transformations, Contract manufacturing of Specialty Enzymes, Fungal Spore formulations for bio-pesticide and other applications, Probiotics for human-healthcare, poultry, aquaculture, agriculture and veterinary applications, custom synthesis of High Value API‘s, intermediates and fine chemicals, Chiral building blocks and scaffolds. Hi Tech Biosciences, a research and development company, is working in the field of Biotechnology, pharmaceuticals and Agriculture, signed an agreement with Holista CollTech Limited, Australia‘s leading manufacturer of natural Health supplements to float a new company Equinox Herbals Private Limited. The new firm would be a joint venture (JV) between the two companies that will develop, patent and commercialize herbal products for various applications worldwide. Holista would market these products globally, since it already has a large customer base and access to over 1,700 distribution points worldwide, providing ready outlets for JV‘s products.
  34. 34. 34 Chandrashekhar Kulkarni MITCON Biotechnology Business Incubation Center, Pune The center was set up in 2004 with the support of the Department of Science and Technology and the Asian and Pacific Center for Transfer of Technology. The goal was to accelerate the setting up of biotech companies by offering an array of business support resources and services. The center‘s credentials were, however, already established well before this, since MITCON has been providing consultancy and training services in diverse industry sectors for over 27 years. ―The decision to start a biotech incubator was a natural progression to the training services MITCON had been providing to people in the biotech sector. ―Their basic aim was to help micro-entrepreneurs in the fields of biotech, agro-biotech and pharma. Currently, they are engaged in fields ranging from biofertilizers to seaweed extracts.‖ The center works on a model of providing subsidized business support. Their working model is different than other incubators. ―While most of them work on the equity model, this is a more plug-n-play sort of an incubator.‖ Any startup in the biotech field would require a minimum of Rs. 20 lakh to a maximum of Rs. 1 crore in initial capital, given the high costs of setting up the lab and hiring skilled manpower. This is where the center steps in with its 2,000-square-feet lab and production facility, skilled workforce and a plethora of ancillary support services—all at concessional rates. ―Entrepreneurs can come to their lab as and when required, develop their products, and then market them to their customers. ―All that they take is a nominal fee that covers their base production and operating costs.‖ The center takes care of all the needs an entrepreneur might have, including packaging, sealing, and even the certification and regulatory requirements that the typical incubatee prefers to stay away from.
  35. 35. 35 Dr Raj Singh, President and Chief Executive Officer, Vivo Biosciences India Vivo Biosciences India is a subsidiary of US based biotech company, Vivo Biosciences Inc, founded in 2005 by technology developer and entrepreneur, Dr Raj Singh. Vivo Biosciences started its R&D operations in India at Lucknow Biotech Park in 2008 via funding from Toucan Capital, USA. Using its patented HuBiogel technology, the company has developed a series of new 3-D or tissue-like assay models emulating the biology of both normal and disease states. These novel human bioassay platforms are expected to accelerate drug discovery, preclinical and biomedical research. The new collaborations in India involve metabolic, genomics and infectious disease research with Central Drug Research Institute (CDRI), Institute of Genomics & Integrative Biology (IGIB), New Delhi and CMC Hospital, Vellore. They are also actively exploring joint venture opportunity for business expansion with Indian, European and US biotech companies (signed CDA with 3 interested parties). Vivo Biosciences has entered into product distribution partnership with Roche, Germany and Global Cell Solutions, USA and has negotiated co-marketing agreement with CROs (Southern Research, Jubilant Biosys, HuMurine). Multiple contracts have been completed or are in progress for oncology services with large pharma companies such as Merck, J&J, OSI and Novartis. In addition to unique oncology and drug toxicity models, Vivo technology offers high- value biomedical applications e.g. personalized medicine (chemotherapy prediction) and implantable devices for stem cell delivery (diabetes, tissue regeneration), the two fastest growing markets.
  36. 36. 36 Shrikumar Suryanarayan chairman, Sea6 Energy At 23, he joined Biocon and directed its R&D ethos and enzymes conquest spiritedly; At 52, with the same raft of energy and agility, he's etching a pioneering entrepreneurial story which has the potential to change the energy ecosystem. His young colleagues at Sea6 Energy are moved by his exuberance and passion. Applied research was always his area of interest and he was fascinated by chemistry. In an era, when being a doctor or an engineer was the trend, he opted for chemical engineering at IIT Madras as the subject was close to his heart. He also did not flow with the tide of going and working abroad or pursuing a career in established companies. He listened to his heart and chased his dreams-first with Biocon and now as chairman of Sea6 Energy. He was always interested in the interface of biology and chemistry. From their interest in capturing energy from seaweeds and algal biofuels during IIT, Sea6 Energy was incubated in July 2010 at IIT Madras campus. Shrikumar and a few IIT Madras alumni contributed about Rs1 crore to get the company started. Sea6 Energy team has achieved several milestones. Starting with the scientific possibility of growing plants on sea and finding the right plants, the stage is now set for technical feasibility. It has also developed technology to allow farmers to grow seaweed in deep waters. They have built a 4,000 sq. ft. farm to grow seaweed and convert seaweed to ethanol. The process for this has been identified. The company's next phase is to move from technical feasibility to commercial viability. It has identified the key enzymes. It plans to build 1sqkm of ocean farm and demonstrate that biofuel can be commercially produced. It plans to achieve this around 2015-2016. It has also entered into a tie up with Novozymes to explore enzymatic technology to produce fuel ethanol, fine chemicals, and protein from seaweed. Novozymes will research, develop, and manufacture enzymes for the conversion process, while Sea6 Energy will contribute its offshore seaweed cultivation technology. It recently raised over Rs3 crore.
  37. 37. 37 Dr. N. Barathi Scientist and Entrepreneur Energy Plantation consultant GROWMORE BIOTECH Ltd., Hosur, Tamil Nadu Dr. Barathi is B. Sc. (Agri), M. Sc (Agri), Ph.D. by educational qualification. Company was established in 1997. The company excelled in proving high quality plants to farmers, industries and Government departments in India and exported to several countries, such as Japan, Australia, South Africa, Hawaii, Miami, Brazil, Malaysia, Singapore, Indonesia, Dubai, Kuwait, Oman, etc. Dr. N. Barathi is currently a member on the sub-committee for hi-tech horticulture formed by the National Planning Commission. He is also on the expert committee formed by National Development Corporation (NCDC), to introduce tissue culture technology in sugarcane. This committee is headed by Commissioner of Agriculture (Govt. of India). Presently Dr. Barathi is Member in State Bamboo Development Agency, Gujarat and "Member" in the Bamboo Technical Support Group (BTSG) under the State Steering Committee of Gujarat and Tamil Nadu. Company started producing 10,000 plants a day and today it has reached a production capacity of 1,00,000 plants a day. They export plants to Japan, Australia, South Africa, Holland, Malaysia, Indonesia, Mauritius, Brazil, etc. In Growmore over 65 plant species are propagated by tissue culture, which includes banana, bamboo, sugarcane, limonium, stevia, patchouli, paulownia, pomegranate, orchids, aloe vera, calla lilly, ornamental foliage plants, such as syngonium, spathiphyllum, cordyline and chlorophytum beside others. Their special clone ―BEEMA‖ of bamboo is thornless, non flowering because of which it is ever growing for the next 200 to 300 years and no snakes find this bamboo as resting place. All industry depends on energy and bamboo can provide a continuous renewable energy at the lowest cost.
  38. 38. 38 B. V. Ravi Kumar XCyton Diagnostics Dr. B.V. Ravi Kumar - is the founder of XCyton, and functions in the capacity of Chairman and Managing Director. Company is founded in 1993. Dr. Ravi Kumar has been instrumental in developing all the products and has successfully launched all the products in the market. Dr. Ravi Kumar's networking abilities have created a huge extended family of collaborators for XCyton. Dr. Ravi Kumar also has been instrumental in getting venture funding, grants and soft loans from Government of India. In XCyton Dr. Ravi Kumar has guided two M.D. dissertations and is currently guiding a Ph.D. Dr. Ravi Kumar was earlier with Astra Research Centre where he was the project coordinator and lead researcher on M. tuberculosis and Neurocysticercosis and also guided a Ph.D. Dr. Ravi Kumar has done his Ph.D in Neurochemistry from Indian Institute of Science. Dr. Ravi Kumar has worked as a registrar in CMC Vellore and has been trained in Psychiatry at CMC Vellore. Dr. Ravi Kumar graduated in medicine from JIPMER, Pondicherry. XCyton envisions to becoming the global leader in Innovative Diagnostic Product development. With the ambition to highlight India on the world map of Medical diagnostics, XCyton is the catalyst for accurate and time management Diagnostics. XCyton ventured into the conception and invention of Molecular Diagnostic products for improved diagnosis of Critical Care Infections, and developed the unparalleled Syndrome Evaluation System, the world‘s first Critical Care Therapeutic Decision Support System. XCyton‘s Syndrome Evaluation System (SES) allows for the simultaneous identification of multiple organisms inclusive of Bacteria, Viruses, Fungi and Parasites, in a specific test from a single sample. This process provides the clinician with a rapid, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens. Previously, XCyton has developed immunodiagnostic kits for infections.
  39. 39. 39 Ravi Kshirsagar Founder and Principal Consultant Inbiosys Consulting He is qualified from Project Management Institute USA, Indian Institute of Management, Calcutta, World Intellectual Property Organization. Product Development Professional turned into project management consultant with 12 years experience in biotechnology in various fields like vaccines, recombinant therapeutics, biosimilars and medical devices. Prior to founding Inbiosys He was associated with top names in Indian biotech fraternity viz Wockhardt, Serum Institute, ReaMetrix and Syngene a Biocon group of Companies. Inbiosys provides project management services to pharmaceutical and biotechnology companies engaged in development, manufacturing and marketing of chemical drugs, biosimilar, vaccines, recombinant proteins and in-vitro diagnostic reagents. Inbiosys serves it clients through its three services: - (1) Establishment of project portfolio management processes (2) Management of third party outsourced projects to CROs and CMOs (3) Project management training (Open house and Corporate)
  40. 40. 40 Dr P. M. Murali Managing Director and CEO, Evolva Biotech He received a PhD in Microbiology and Microbial Technology from Madurai Kamaraj University. Dr. Panchapagesa Murali has been the Chief Executive Officer of Evolva Biotech Private Limited, the Company‘s Indian subsidiary, since September 2006. Dr. Murali has over 20 years of experience in pharmaceutical & health care R&D, including management of more than ten clinical trials, in particular in respiratory diseases. Previously, he was Founder and Director (for 16 years) of Dalmia Centre for Research and Development, developing and launching natural product-based therapeutics, and Founder and Chairman of MLC & Netpeople group of IT & Telecom companies (networking solutions, banking security and communication services). Dr. Murali is a former Indo-US scientist at Battelle-Kettering, Ohio, and fellow of Unilever India. Dr. Murali is the President of the Association of Biotechnology Led Enterprises in India. He is on the Board of Dalmia Research and Development Limited and a member of the Governing Board of Dalmia Centre for Research and Development. Dr. Murali is Vice-President and Treasurer of the Indian Red Cross Society. He is also Chairperson of the Biotech panel of the Confederation of Indian Industries Tamil Nadu and a member of the Vision Group of the Government of Karnataka. Dr P M Murali, is president, Association of Biotechnology Led Enterprises (ABLE).
  41. 41. 41 Dr. Rajeev Soni President, COO, Premas Biotech Rajeev Soni is a Ph.D. in Molecular Biology and Biotechnology from the University of Cambridge, U.K. and has over 20 years of research and development experience including industry and academia. He has been responsible for the design and management of state of the art molecular biology labs at Lidak (Avanir) Pharmaceuticals, La Jolla, USA, De Montfort University, Leicester, U.K., The Naval Research Lab, Washington D.C., USA, Ranbaxy biotechnology, Gurgaon, India and at PREMAS, Gurgaon, India. He has managed mutli-skilled and mutli-lingual teams across various functions and countries. In 2005, he founded Premas Biotech, along with a team of entepreneurs and investors and served as President and COO from inception till Jan. 2012. He was responsible for in-house and contract research and development. He managed marketing and business development aspects of the business as well and has keen understanding of the life science market in India, Europe and USA. He is currently serving as Associate Vice President R&D at Biocon Ltd. He was part of the implementation team for "Lean Management" or the "Toyota production Process" at PREMAS; possibly, one of the first companies in India to implement this in the biology sector coupled with electronic lab-notebook and SDMS for a 21CFR part 11 compliant set up. He has successfully delivered over 150 proteins in 4 years while at PREMAS from mg to gm levels. His area of specialization is varied and includes Innovative drug discovery research for Cancer and Infectious diseases focusing on both NCE's and Bio-therapeutics, CRAMS (contract research and manufacturing services), enzyme engineering for biofuels, development and refinement of systems for protein expression in E. coli, yeast and mammalian cells, fund raising, strategic planning, consulting for biosimilar and novel bio-therapeutics and business development in the biotech sector.
  42. 42. 42 Taher Abbasi (Co-Founder and CEO) Pradeep Fernandes (Co-Founder & President) Cellworks Group Inc. Cellworks was founded in 2005 in California with R&D center in Bangalore. Artiman Ventures and Sequoia Capital are its investment partners. Cellworks is a therapeutics design company using simulation to screen studies and predict clinical outcomes. Tahir Abbasi holds a B.S. in Electronics from University of Bombay; M.S. in Computer Engineering from California State University, Northridge; MBA from University of California, Los Angeles and National University of Singapore and alumni of BioExec Institute at University of California, Berkeley. Prior to co-founding Cellworks Group Inc., he held senior management positions in Cadence Design Systems, Get2Chip, Vitalect and Synopsys. He serves on the Board of Cellworks Group Inc. Taher is the co-author of the books ―Logic Synthesis Using Synopsys‖ (Kluwer publication) and ―It‘s the Methodology, Stupid!‖ (ByteK Publication). He has also written and presented many articles in scientific publications and industry conferences worldwide. Taher was an adjunct faculty in extension programs of University of California, Santa Cruz and University of California Irvine. Taher Abbasi has over twenty years of technology and global operations setup and management experience. His specialization is automation engineering in the semiconductor and life sciences therapeutics industries. He was part of core team involved in establishing the Cellworks R&D operations and processes in Asia; global research collaborations and developing strategy for implementing Cellworks proprietary technology automation infrastructure to emulate disease physiology computationally and designing therapeutics pipeline. Pradeep Fernandes is Co-founder and President, Technology of Cellworks Group. He has over twenty years of experience in semiconductor engineering and life sciences. He has applied the engineering approaches and technologies to develop the mathematical solver engines and automation infrastructure for the Cellworks proprietary technology for emulating disease physiology computationally. He is a prolific entrepreneur and also an angel investor in the technology space and sits on the boards of a few private companies and non-profit organizations.
  43. 43. 43 Sachin Purohit Founder, Managing Director, Geneombio Technologies, Pune, India Resilient Cosmeceuticals Pvt. Ltd. He is B. Sc. (Chemistry), MBA (Marketing) from USA. He also has worked with several international companies of repute including Microsoft and Pharmacia Upjohn. Gene Support is a collaborative venture of GeneOmbio Technologies Pvt. Ltd., DNAlysis Biotechnology and Resilient Cosmeceuticals Pvt. Ltd. GeneOmbio Technologies Pvt. Ltd. is a company providing Molecular Diagnostic Services, Contract Research Services, and Animal Genetic Services. A contract research organization with a strong focus on genomics and molecular biology, GeneOmbio Technologies executes R&D projects of economic significance for private sector pharmaceutical companies as well as Government organizations. Its human molecular diagnostic division provides advanced human pathogen detection services based on state-of- the-art fluorescent chemistry and Real Time PCR Platforms. As the only veterinary genetics service provider in India, the company provides advanced genetic disorder screening, paternity verification and molecular marker assisted selection in cattle and buffalo for milk production traits in the organized dairy sector of the country. The Company researches, develops and manufactures basic research kits for DNA and RNA based laboratories. It also develops molecular diagnostic kits suited for rapid detection of human and animal pathogens using different PCR machines. An NABL accredited, ISO17025:2005 certified company, GeneOmbio Technologies is an R&D Facility recognized by Department of Science & Industrial Research, Ministry of Science & Technology, Government of India. It is a recipient of the ISBA Entrepreneur Award in 2009. The company‘s emphasis is on the relationship between genes, nutrition and lifestyle in determining health and wellness. In this context their gene tests provide a valuable tool for the management of health and wellness. It uses cutting-edge molecular technologies to provide clients with reliable, high-quality services, performed according to the highest international standards. DNAlysis comprises a dedicated team of scientists with expertise in Human Genetics, Mol. Biology, Nutritional Genomics and Dietetics.
  44. 44. 44 Jitendra N Verma Founder & Managing Director, Lifecare Innovations (P) Ltd. He is M.Sc. from Allahabad University and PhD from PGIMER. Company was incorporated as Medical Biotechnology Company specializing in novel drug delivery system (NDDS) in November 2000. Academician, Scientist and Industrialist, Dr Jitendra N Verma is the Founder Managing Director of Lifecare Innovations. He has 34 years of academic and industrial research experience. Dr. Verma was engaged in medical research at University of Pennsylvania, Northwestern University, Georgetown University and Walter Reed Army Institute of Research in USA. Known for his expertise in Life Sciences & Biotechnology, Dr Verma was acclaimed for promotion of R&D and commercializing their outcome by industry-academia interactions and public-private partnerships. Dr Verma has pioneered development of NDDS based Liposomal and Nano-Drugs. As a leader in Liposome technology application for drugs, diagnostics and vaccines, Dr Verma developed and commercialized India's first Liposomal product and world's only liposomal diagnostic - Liposome agglutination test for Syphilis. He has contributed to Asia's first and world's best anti-fungal drug FUNGISOME - a Liposomal Amphotericin B. Working on malaria vaccine Dr Verma was the first to report that Liposomal vaccines elicit cellular immune response necessary for protective immunity. Dr Verma is presently involved in developing Liposomal and Nano-Drugs for treatment of Tuberculosis, Cancer, Leishmaniasis and Fungal infections. Keenly involved in translational research for taking benefits of Science & Technology by applications in everyday life, Dr Verma has a number of publications, reviews and patents to his credit. He is conferred with the title of Vigyan Ratna and is the recipient of national, international and state awards & honors. Lifecare Innovations is the winner of DSIR (Department of Science & Industrial Research, Ministry of Science & Technology, Government of India) National Award 2006 for R&D Efforts in Industry.
  45. 45. 45 Mr. Vinod Wahi Founder Chairman & CEO, KHC Healthcare India Private Limited The company was established in 2005. He is Alumni of Delhi University, Graduate in Chemistry, Postgraduate in Sales and Marketing from Faculty of Management Studies. Mr. Wahi believes in teamwork. Anuj Wahi, 35, is the Managing Director of KHC Healthcare India Private Limited and Co-Founder & President of KanHealthcare, effective November 9th, 2005. Mr. Wahi initiated and created the concept of Clinical Diagnostics in early 70's to bring in a revolutionary change in performing laboratory investigations in India. For this, he was trained extensively by Boehringer Mannheim in different parts of world, including his stay at Boehringer Mannheim, Montreal, Canada for many months. Mr. Wahi travelled extensively all over India to create strong awareness on advancement in Diagnostics and developed a dependable infrastructure to create customers confidence. Rapid acceptances of advanced technology then lead competitors to enter Indian Market. He served Boehringer Mannheim, subsequently acquired by Roche, for many years as its General Manager, Diagnostics and was also on the board of BMK to take up manufacturing of Diagnostic Reagents and Equipment. Starting from nil sales, Boehringer Mannheim, under his leadership as the Country Head,, reached US $ 6.0 million in India when he decided to move to Delhi from Mumbai to join Wipro Biomed as its CEO, India in March 1990. Mr. Wahi replicated the Business Model and added the concept of "Scientific Marketing" to focus on training, presence in referral Hospitals & Institutions and winning projects at premium over competitors. He diversified into clinical diagnostics, medical and life sciences by having alliances with world leaders and focussed extensively on Beckman Coulter, Fujinon, Hewlett Packard (Agilent) and Promega. He also added Mission Quality by implementation of 6 sigma and toll free call centre. Under his leadership, sales of Wipro Biomed continued to grow and reached US $ 17.0 million in India in the year 2005-06, when he decided to set up his own organization by synthesizing his 3 decades of learning to develop KHC Healthcare India Private Limited.
  46. 46. 46 Dr Mallik Sundaram, President and CEO (Founder), Mitra Biotech Company started in 2008 and has made commendable progress in innovation and research. Research is oriented towards spinning off new technology in the area of personalized cancer care to patients. Mallik was instrumental in developing M- Enoxaparin, Momenta‘s first Billion dollar drug and three other lead drug candidates through various stages of regulatory approval in the U.S. Mallik obtained his Ph.D. in Biotechnology from the University of Utah, Salt Lake City, UT and MBA from the Wharton Business School, University of Pennsylvania. Dr Sudaram prior to the association with Mitra was a scientific co-founder of Momenta Pharmaceuticals. He was instrumental in developing M-Enoxaparin, Momenta‘s first billion dollar drug and three other lead drug candidates through various stages of regulatory approval in the US. He has been an adjunct faculty in the department of Bioengineering (2000-07) and the Department of Chemical Engineering (2007 to till date) at the Massachusetts Institute of Technology, Cambridge, US. He has over 50 publications and 12 patents. Mitra Biotech is a translational company focused in offering personalized cancer care to patients through its proprietary pre- clinical model CANScript. The CANScript technology enables physicians to select the most optimal drug or drug combination for a patient under investigation, there by shortening the treatment period and avoiding toxicity that arises from non- optimal drugs. The assays are carried out on patients‘ own tumors by recreating human-tumor microenvironment on plates to ensure high specificity. The turnaround time for this service is less than a week and it works for multiple solid as well as haematological cancers. The technology can be used to test chemotherapeutics, biological molecules and immuno- modulators. CANScript has started taking a global shape already with hospitals in the US and India interested in using it for patient care. Dr. Pradip K Majumdar is CSO and (co- founder) of Mitra Biotech.
  47. 47. 47 Founders, Prof Shiladitya Sengupta and Dr. Raghunath Mashelkar Invictus Oncology, New Delhi Prof Shiladitya Sengupta an assistant professor of medicine at Harvard Medical School and Dr Raghunath Anant Mashelkar, former director general, Council for Scientific and Industrial Research (CSIR) joined hands to transform their ideas into a reality. This startup is outcome of sheer passion and determination of two scientists. As cancer treatment is increasingly becoming combination therapy, Invictus is developing a platform technology that optimizes more effective drug combinations in a plug and play manner, such that they are specifically delivered to the tumor and not to other parts of the body. This can increase efficacy and reduce side effects of cancer therapy. Since innovative activities are carried out in a time-bound manner to develop cancer therapeutics, the department of scientific and industrial research (DSIR), has registered Invictus as an in-house R&D unit. By virtue of this recognition, Invictus can avail a number of fiscal incentives for R&D and is eligible for receiving grants from the government of India. The synthetic chemistry team at Invictus harnesses the full potential of platinum- based drugs used as first line of therapy in over 70 percent of all cancers. These novel platinum-based drugs are engineered using structure activity relationships for increased efficacy with reduced side effects. The company is developing a portfolio of Antibody Drug Conjugates (ADCs), based on its proprietary linker chemistry. ADCs are meant for tumor-specific targeted drug delivery. During its first round of fund-raising, the company has raised `10.50 crore from investors, Navam Capital and Aarin Capital. Navam Capital is a venture capital firm focused on making seed and early-stage investments in energy, technology and healthcare. The company has pending patent applications directed to cytotoxic ligand- targeted molecules and ligand drug conjugates and novel lipid-based nanoparticle chemotherapeutics comprising novel platinum compounds. Invictus envisions bringing together a broad coalition of industry, academia, hospitals, patient advocates, policy makers and regulators and has already partnered with academicians from leading Institutions to form valuable public-private partnerships (PPP).
  48. 48. 48 Dr Binay Panda and Dr Vijay Chandru (CEO of Strand Life Sciences) Genomics Application and Informatics Technology Labs (GANIT labs) GANIT Lab‘s mandate is to do India-specific genomic research. Work at GANIT ranges from whole genome sequencing to primary and secondary data analysis, microarray (including standard gene expression and methylation experiments), capillary sequencing (using Sanger capillary methods) and Quantitative PCR. The work can lead to deciphering and understanding the vast genomic and proteomic data of the post-genomic era to combat diseases like cancer, diabetes or cardio vascular problems. Dr Panda, is PhD in molecular virology from the Oxford University and an American Cancer Society post doctoral fellow, who returned back to India to do something in the not so much talked about area, Dr Chandru too was very enthusiastic about the same. The founders felt that there was tremendous scope for small-scale application driven research in genomics that nobody was doing at the given point and time. GANIT labs, a public-private partnership (PPP) initiative between Institute of Bioinformatics and Applied Biotechnology and Strand Life Sciences, works exclusively in the area of DNA sequencing. Genomics Application and Informatics Technology Labs also known as GANIT labs, is a genome sequencing and translational genomics bio-IT centre based in Bangalore. It is a not-for-profit, government-funded, public-private partnership initiative between Institute of Bioinformatics and Applied Biotechnology (IBAB) and Strand Life Sciences. GANIT Labs is a genome sequencing and translational genomics lab based in Bangalore, India. The lab uses second generation sequencing instruments, compute clusters and human brains to sequence analyze and interpret genome data from variety of organisms. The generous funding of `20 crores from government agencies (Department of Information Technology, Government of India and Department of Information Technology, Biotechnology and Science and Technology, Government of Karnataka), and an almost equal amount from Strand, helped the company to spearhead its activities.
  49. 49. 49 Mr. R.P Krishnamachari Founder, Managing Director / CEO Tex Biosciences (P) Limited Mr. Krishnamachari is the founder and first generation entrepreneur of Tex Biosciences. A Chemical Engineer by qualification, Mr. Krishnamachari holds 30 years of operational and managerial experience in the Bio-tech industry. He is credited with installing state of the art production facilities at Tex Biosciences. Company was started in 1979. In 1982, Tex Biosciences turned into a corporate body to widen its infrastructure and to meet the increasing demands for its products. The organization has diversified into other markets and is now seen as an industry leader in Biotechnology and leather chemical products. Today company‘s turnover is 15 million USD. Tex Biosciences was formerly known as Textan Chemicals Pvt. Ltd. It produces enzymes for various applications like leather processing, for paper & pulp industry, animal feed processing, detergent, textile industry etc. Company is built on the principles of innovation, quality conscious and future focus. The principles have stood the test of time and served the organization in good light. Company believes and practices social responsibility, the organization is committed to fair and ethical business practices and supports the local communities in every way possible. Innovativeness has been a way of business at Tex Biosciences. The R&D team in keeping with the organization's customer centric approach works closely with its customers to develop and formulate auxiliaries that are quality import substitutes. The latest addition to product range is Ezyme - A, a 100% Sulphide-Lime Free unhairing Enzyme, the first of its kind in India. The invention of this Enzyme by Tex Biosciences speaks about company's commitment to cleaner environment. Tex Biosciences group includes Rajam Chemicals and Nature Remedies (P) Limited (for herbal formulations). Company has ties with leading scientific and technical organizations.
  50. 50. 50 Dr Mosuvan Kuppusamy Founder, CSO, Managing Director, Tergene Biotech Dr Mosuvan Kuppusamy, is a well-known biotechnologist being well known in the vaccine industry with three decades of experience in research and manufacturing of biologics. He was associated earlier with the various prominent companies. He wanted to follow his heart and finally decided to start his own venture. The company started its research and development (R&D) activities in the year 2010 by acquiring lab space in Biotechnology Incubation Center, Hyderabad. Focus was in developing affordable vaccines against infectious diseases based on the polysaccharide-carrier protein conjugate platform. Besides vaccines against infectious diseases, Tergene is working on the development of therapeutic vaccines against antibiotic resistance, cancer and allergy. Tergene is developing bio-conjugate platform technologies for novel vaccines and antibody drug conjugates. It has developed the multivalent pneumococcal conjugate vaccine (PCV- 15) employing an innovative micro reactor based conjugation chemistry. Initial funding support for the PCV-15 project was received from BIRAC. Tergene was awarded with Biotechnology Industry Research Assistance Council (BIRAC) Innovators Award-2013 in the Healthcare sector. Another significant achievement of the company is the development of a cost effective production technology for CRM- 197, the safest carrier protein and a key ingredient in the development of PCV-15. It also finds application in other therapeutic vaccines against cancer and allergy. The company is setting up a manufacturing facility (as per GMP norms) near Chennai, Tamil Nadu. The state-of-the-art facility will be operational by the end of 2014 and will be used to manufacture vaccines, biopharmaceuticals and probiotics. This state-of-art manufacturing facility will comply US FDA specifications. The company has rich R & D team and has successfully developed technologies for the production of various vaccines and biosimilars. Acellular Pertussis (ACP) vaccine, Haemophilus influenzae type B (HiB) conjugated vaccine, Typhoid Vaccine, Streptokinase, Botulinum toxin A, Terinase - a thrombolytic enzyme are some of the technologies.

×